PharmD student prepares COVID-19 vaccine
32nd New Drugs and Modern Concepts in Pharmacotherapy
Program Topics
  • 2021 New Law Updates
  • ADHD
  • BEERS Criteria Updates
  • Depression Treatments
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Medical Cannabis
  • Migraine Prevention
  • Multiple Sclerosis
  • Pain Management
  • Pediatric Immunization

Accreditation

Course Overview

This knowledge and application-based learning activity is designed to provide pharmacists with the most current information regarding new drugs and new indications for older drugs. Lecture topics have been selected to reflect major areas of advancement in clinical therapeutics. The target audience for this program are pharmacists in a variety of settings including outpatient clinical care, managed care, consulting and inpatient-based practice.

Pharmacists

The University of the Pacific, Thomas J. Long School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for pharmacists for a maximum of 15 hours of continuing education credit (1.5 CEU), all application-based and are numbered 0006-0000-21-001-L08-P, 0006-0000-21-002-L01-P, 0006-0000-21-003-L06-P, 006-0000-21-004-L01-P, 0006-0000-21-005-L03-P,  006-0000-21-006-L03-P, 0006-0000-21-012-L05-P, 0006-0000-21-007-L01-P, 0006-0000-21-008-L01-P, 006-0000-21-009-L01-P, 0006-0000-21-010-L01-P, 0006-0000-21-011-L01-P.

To receive continuing education credit for this program, pharmacists must attend each of the program sessions, complete and turn in the program registration form with all proper codes issued to participants and evaluation form for each day prior to departing the conference. Statements of credit will be uploaded to participant NABP e-profiles via CPE Monitor within 30 days of completion of the program. Paper statements will not be mailed. These are ongoing programs with an initial release date of 04.17.2021.

Planning Committee

Nancy L. DeGuire, PharmD, Clinical Professor of Pharmacy Practice and Director for Postgraduate Professional Education, Thomas J. Long School of Pharmacy, University of the Pacific

Julio R. Lopez, PharmD, Retired pharmacist

Linda L. Norton, PharmD, Professor and Chair, Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific

Staff

Dua Her, Director of External Relations and Professional Development, Thomas J. Long School of Pharmacy, University of the Pacific

Becky Perry, Alumni Relations Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific

Contact Us

pharmacyce@pacific.edu
209.932.3275


In accordance with ACPE policies, all Planning Committee members were required to complete a "Declaration of Disclosure-Conflict of Interest Statement" prior to this educational activity. All have indicated no relationship to disclose relating to the subject matter of these presentations.

Saturday, April 17

Time Session Speaker
10 - 11 a.m. Updates in Chronic Pain Management
0006-0000-21-001-L08-P | 0.1 CEU
  1. Describe the biopsychosocial model for the treatment of chronic pain.
  2. List non-opioid medications, their mechanisms of action, and their indications for the treatment of pain.
  3. Identify risks associated with chronic opioid use.
  4. Apply the biopsychosocial approach to a chronic pain patient case.
Elizabeth Son, PharmD, PhD

Pain Management Clinical Pharmacy Specialist, San Francisco VA Health Care System
11 a.m. -
12 p.m.
Multiple Sclerosis Management and Treatment
0006-0000-21-002-L01-P | 0.1 CEU
  1. Describe the acute, long-term and symptomatic pharmacologic treatment of multiple sclerosis.
  2. Delineate the efficacy, side effects and monitoring required for select multiple sclerosis therapies.
  3. Apply the appropriate treatment plan in multiple sclerosis patient cases.
Elina Melamed, MD

Staff Physician, Department of Neurology, VA Northern California Health Care System
12 - 1 p.m. Break
1 - 2 p.m. Immunization Updates for Pediatric Patients
0006-0000-21-003-L06-P | 0.1 CEU
  1. List the immunizations that are utilized in the pediatric population.
  2. Analyze a pediatric patient case to determine immunization needs.
  3. Identify which pediatric immunizations are live or inactivated to determine vaccine timing.
  4. Describe newer ACIP recommendations for pediatric patients.
Veronica T. Bandy, PharmD, MS, FCPhA, FCSHP, BCACP

Clinical Professor, Sacramento Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific
2 - 3 p.m. New Drugs in Select Gastrointestinal Disorders
006-0000-21-004-L01-P | 0.1 CEU
  1. Discuss broadly the clinical presentation and diagnostic criteria related to irritable bowel disease (IBS) and inflammatory bowel disease (IBD).
  2. Identify the new drugs which have been approved for IBS and IBD.
  3. Discuss the mechanism of action, adverse drug reactions, and monitoring parameters associated with each new drug.
  4. Discuss the clinical role and place in therapy of new drugs approved for IBS and IBD.
Deepti Vyas, PharmD

Associate Professor, Director of Interprofessional Education and Instructional Design, Thomas J. Long
School of Pharmacy, University of the Pacific

 

Sunday, April 18

Time Session Speaker
9 - 10:30 a.m. 2021 New Pharmacy Laws Update
0006-0000-21-005-L03-P | 0.15 CEUs
  1. Describe the changes in State and Federal laws for 2021.
  2. Explain the overarching trends in the regulatory climate for California pharmacists.
  3. Summarize new standards of practices in pharmacy.
  4. Identify resources for staying current on changing regulatory issues.
  5. Evaluate the role of CURES for pharmacists in meeting their corresponding responsibility.
Tony J. Park, PharmD, JD

Principal Attorney at CPL-California Pharmacy Lawyers; General Counsel for California Pharmacists
Association; Legal Counsel for California Korean-American Pharmacists Association; Pharmacy
Law and Ethics Professor, Western University, University of the Pacific, and Chapman University
10:30 -
10:45 a.m.
Break
10:45 a.m. - 12:15 p.m. How the Government Wants Pharmacists to Decline Controlled Substance Prescriptions
0006-0000-21-006-L03-P | 0.15 CEUs
  1. Outline controlled substance enforcement trends by government agencies.
  2. Construct a risk mitigation and compliance strategy.
  3. Scrutinize common pharmacy practices for controlled substance dispensing.
  4. Dispel common myths and misunderstandings regarding government enforcement of controlled substance prescriptions.
  5. Understand how to lawfully decline controlled substance prescriptions to seemingly legitimate patients.
Tony J. Park, PharmD, JD

Principal Attorney at CPL-California Pharmacy Lawyers; General Counsel for California Pharmacists
Association; Legal Counsel for California Korean-American Pharmacists Association; Pharmacy
Law and Ethics Professor, Western University, University of the Pacific, and Chapman University
12:15 -
1:15 p.m.
Break
1:15 -
2:15 p.m.
BEERS Criteria in Clinical Practice
0006-0000-21-012-L05-P| 0.1 CEU
  1. Identify three drug therapy changes in the recently revised BEERS Criteria.
  2. Cite two significant additions or deletions to the newest BEERS Criteria.
  3. Describe the Delphi process.
  4. Name three medications usually best avoided for elders.
Lee Meyer, PharmD, BCGP, FASCP, FCPhA

Principal Owner, M2: Pharmacist Service

 

Saturday, April 24

Time Session Speaker
10 - 11:30 a.m. Migraine Headaches: Update on the Pathophysiology, Clinical Presentation, Management and the Role of the Pharmacist
0006-0000-21-007-L01-P | 0.15 CEUs
  1. Describe the pathophysiological mechanisms and the clinical signs and symptoms of migraine.
  2. Recognize medication-over-use-headache (MOH) and the criteria that supports its clinical diagnosis.
  3. List some non-pharmacological interventions available for the management of migraine.
  4. List the commonly used and recently approved abortive (acute) and preventative (prophylactic) medications and their role in the management of migraine headache.
  5. Define the role of the pharmacist in the management of migraine headaches.
  6. Apply the presented migraine guidelines to a patient case to make an appropriate recommendation.
George DeMaagd, PharmD, BCPS

Professor of Pharmacy and Associate Dean of Academic Administration, Union University College of Pharmacy
11:30 a.m. - 12:30 p.m. Break
12:30 -
2 p.m.
Current Advances in Depression Treatment
0006-0000-21-008-L01-P | 0.15 CEUs
  1. Review current strategies for the treatment of depression.
  2. Examine common errors in the diagnosis of depression.
  3. Present the new mechanism of action for medications utilizing the glutamate system.
  4. Discuss current strategies and new medication for postpartum depression.
  5. Compare and contrast updated guidelines for child and adolescent depression to past guidelines.
  6. Apply the information regarding esketamine nasal spray to a patient case.
Kimberly A. Hoffmann PharmD, APh, BCPP, BCGP

Clinical Professor and Bakersfield Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific
2 - 3 p.m. Medical Cannabis - What Pharmacists Want to Know
006-0000-21-009-L01-P | 0.1 CEU
  1. Describe the basic pharmacology and potential therapeutic uses ofmedical cannabis.
  2. List administration methods, side effects and patient safety issues withmedical cannabis.
  3. Discuss essential patient counseling points for the safe use of cannabis products.
  4. Review legal considerations regarding the use of medical cannabis.
Deborah Yurovich-Berlekamp, PharmD, BCPS

Assistant Professor of Pharmacy Practice, The University of Findlay College of Pharmacy

 

Sunday, April 25

Time Session Speaker
10 a.m. -
12 p.m.
Review of the Top Papers in Infectious Diseases from 2019-2020
0006-0000-21-010-L01-P | 0.2 CEUs
  1. Review the importance of staying up to date with the Infectious Diseases literature.
  2. Discuss the most relevant articles published in the field of Infectious Diseases in 2019-2020.
  3. Apply the literature to the changing practice of Infectious Diseases.
  4. Discern the potential weaknesses of the papers published.
  5. Discern the practice areas where there continues to be controversy in ID practice.
  6. Summarize the most important changes in ID practice.
Hien H. Nguyen, MD, MAS

Section Chief, Infectious Diseases, VA Northern California Health Care System; Professor of Medicine and
Vice Chief, Division of Infectious Diseases, UC Davis Health
12 - 1 p.m. Break
1 - 2 p.m. Surviving and Thriving with ADHD
0006-0000-21-011-L01-P | 0.1 CEU
  1. Discuss the age-specific treatment goals and recommendations for children and adults with ADHD.
  2. Provide case examples whereby certain stimulant formulations may be more advantageous in a certain age or patient population.
  3. Compare stimulant treatments with each other and with nonstimulants regarding efficacy, formulations, and side effects.
  4. Counsel patients, parents, and caregivers on managing common side effects of ADHD medications.
  5. Discuss the potential long-term and rare side effects of stimulants.
Julie Ann Dopheide, PharmD, BCPP, FASHP

Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, University of Southern California School of Pharmacy and Keck School of Medicine; PGY2 Psychiatric Pharmacy Residency
Program Director

Veronica T. Bandy, PharmD, MS, FCPhA, FCSHP, BCACP
Clinical Professor, Sacramento Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific

George DeMaagd, PharmD, BCPS
Professor of Pharmacy and Associate Dean of Academic Administration, Union University College of Pharmacy

Julie Ann Dopheide, PharmD, BCPP, FASHP
Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, University of Southern California School of Pharmacy and Keck School of Medicine; PGY2 Psychiatric Pharmacy Residency Program Director

Kimberly A. Hoffmann PharmD, APh, BCPP, BCGP
Clinical Professor and Bakersfield Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific

Elina Melamed, MD
Staff Physician, Department of Neurology, VA Northern California Health Care System

Lee Meyer, PharmD, BCGP, FASCP, FCPhA
Principal Owner, M2: Pharmacist Service

Hien H. Nguyen, MD, MAS
Section Chief, Infectious Diseases, VA Northern California Health Care System; Professor of Medicine and Vice Chief, Division of Infectious Diseases, UC Davis Health

Tony J. Park, PharmD, JD
Principal Attorney at CPL-California Pharmacy Lawyers; General Counsel for California Pharmacists Association; Legal Counsel for California Korean-American Pharmacists Association; Pharmacy Law and Ethics Professor, Western University, University of the Pacific, and Chapman University

Elizabeth Son, PharmD, PhD
Pain Management Clinical Pharmacy Specialist, San Francisco VA Health Care System

Deepti Vyas, PharmD
Associate Professor, Director of Interprofessional Education and Instructional Design, Thomas J. Long School of Pharmacy, University of the Pacific

Deborah Yurovich-Berlekamp, PharmD, BCPS
Assistant Professor of Pharmacy Practice, The University of Findlay College of Pharmacy


In accordance with ACPE policies, all speakers were required to complete a "Declaration of Disclosure-Conflict of Interest Statement" prior to this educational activity. All have indicated they either have no relationship to disclose relating to the subject matter of their presentation or any conflicts were resolved using industry standard best practices. Please refer to each session's materials for conflict disclosures.